The new offerings arrive as large enterprise payers increasingly favor integrated, multi-condition solutions over fragmented point-care services. Both programs are slated for a fall 2026 rollout across the company's Fortune 500 client base, with revenue contributions expected to begin in the fourth quarter of that year. By folding these modules into its existing infrastructure, the company intends to address high-cost clinical needs—such as menopause-related metabolic syndrome and obstructive sleep apnea—through a single, cohesive interface.

Dario Women provides support for perimenopause and menopause, offering clinical evaluations for hormone replacement therapy where appropriate. Meanwhile, the sleep program addresses obstructive sleep apnea, a condition linked to significantly higher annual medical expenditures. The module facilitates home sleep testing and provides patients with a range of treatment pathways, from behavioral coaching to CPAP therapy or GLP-1 medications. According to CEO Erez Raphael, these additions are essential for strengthening the company's ability to support members across their entire healthcare journey while diversifying revenue streams beyond standard digital engagement.